Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Market Cap	2.56B
Revenue (ttm)	170.03M
Net Income (ttm)	-83.32M
Shares Out	95.95M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,151
Average Volume	108,171
Open	27.00
Previous Close	26.65
Day's Range	26.25 - 27.00
52-Week Range	19.80 - 40.00
Beta	-0.06
RSI	62.01
Earnings Date	Aug 13, 2025

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6704

Financial Performance

In 2024, TPEX:6704's revenue was 170.03 million, an increase of 20.44% compared to the previous year's 141.18 million. Losses were -83.32 million, -5.41% less than in 2023.